Back to top
more

Endocyte, Inc. (ECYT)

(Delayed Data from NSDQ)

$23.99 USD

23.99
NA

0.00 (0.00%)

Updated Dec 20, 2018 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

What to Expect from Endocyte (ECYT) Stock for Q1 Earnings?

Endocyte, Inc (ECYT) is expected to report first-quarter 2017 results on May 3.

    Endocyte (ECYT) Up 3.5% Since Earnings Report: Can It Continue?

    Endocyte (ECYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Swarup Gupta headshot

      5 Cheap Breakout Stocks for Superb Returns

      The technique identifies those stocks whose prices are fluctuating within a specific band.

        Endocyte (ECYT) Reports Wider-than-Expected Loss in Q4

        Endocyte, Inc. (ECYT) reported a fourth-quarter 2016 loss of 26 cents per share, wider than both the Zacks Consensus Estimate of a loss of 25 cents and the year-ago loss of 23 cents.

          Endocyte (ECYT) Shares March Higher, Can It Continue?

          Endocyte, Inc. (ECYT) has been on the move lately as the stock has risen by 20.2% in the past four weeks, and it is currently trading well above its 20-Day SMA

            Endocyte (ECYT) Reports a Wider Q4 Loss

            Endocyte reported a loss per share of 26 cents per share while our consensus called for a loss of 25 cents per share.

              Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards?

              Endocyte, Inc (ECYT) is expected to report fourth-quarter 2016 results on Mar 1. The company has an impressive track record, having beaten estimates on three of the trailing four quarters and reporting in-line results in the remaining quarter

                Valeant Streamlines Portfolio with Skincare Brands Sale

                Beleaguered Valeant Pharmaceuticals International, Inc. (VRX) announced that it has entered into an agreement to sell its CeraVe, AcneFree and AMBI skincare brands to L'Or??al for $1.3 billion in cash.

                  Valeant to Sell Dendreon Unit to Sanpower for $820 Million

                  Beleaguered Valeant Pharmaceuticals International, Inc. (VRX) announced that it will sell all the outstanding equity interests in Dendreon Pharmaceuticals, Inc. to the China based Sanpower Group Co., Ltd.

                    Is Valeant (VRX) Fated for Terrible 2017 As Well?

                    Shares of Valeant Pharmaceuticals, Inc. (VRX) slumped 85.3% in 2016, eroding a chunk of shareholders' net worth.